462 related articles for article (PubMed ID: 27418274)
21. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy.
Gasch O; Camoez M; Dominguez MA; Padilla B; Pintado V; Almirante B; Molina J; Lopez-Medrano F; Ruiz E; Martinez JA; Bereciartua E; Rodriguez-Lopez F; Fernandez-Mazarrasa C; Goenaga MA; Benito N; Rodriguez-Baño J; Espejo E; Pujol M;
Clin Microbiol Infect; 2013 Nov; 19(11):1049-57. PubMed ID: 23331461
[TBL] [Abstract][Full Text] [Related]
22. Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores.
Kim SH; Park WB; Lee CS; Kang CI; Bang JW; Kim HB; Kim NJ; Kim EC; Oh MD; Choe KW
Clin Microbiol Infect; 2006 Jan; 12(1):13-21. PubMed ID: 16460541
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.
Hu HC; Kao KC; Chiu LC; Chang CH; Hung CY; Li LF; Liu TP; Lin LC; Chen NH; Huang CC; Yang CT; Lu JJ
BMC Infect Dis; 2015 Oct; 15():444. PubMed ID: 26497595
[TBL] [Abstract][Full Text] [Related]
24. Gender affects prognosis of methicillin-resistant Staphylococcus aureus bacteremia differently depending on the severity of underlying disease.
Kang CK; Kwak YG; Park Y; Song KH; Kim ES; Jung SI; Park KH; Park WB; Kim NJ; Kim YK; Jang HC; Lee S; Jeon JH; Kwon KT; Kim CJ; Kim YS; Kim HB;
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1119-1123. PubMed ID: 29667110
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan.
Lin SH; Liao WH; Lai CC; Liao CH; Tan CK; Wang CY; Huang YT; Hsueh PR
J Antimicrob Chemother; 2010 Aug; 65(8):1792-8. PubMed ID: 20511366
[TBL] [Abstract][Full Text] [Related]
26. Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis.
Casapao AM; Jacobs DM; Bowers DR; Beyda ND; Dilworth TJ;
Pharmacotherapy; 2017 Nov; 37(11):1347-1356. PubMed ID: 28949410
[TBL] [Abstract][Full Text] [Related]
27. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
[TBL] [Abstract][Full Text] [Related]
28. Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillin-resistant Staphylococcus aureus bacteremia.
Yoon YK; Park DW; Sohn JW; Kim HY; Kim YS; Lee CS; Lee MS; Ryu SY; Jang HC; Choi YJ; Kang CI; Choi HJ; Lee SS; Kim SW; Kim SI; Kim ES; Kim JY; Yang KS; Peck KR; Kim MJ
Antimicrob Agents Chemother; 2014; 58(1):317-24. PubMed ID: 24165181
[TBL] [Abstract][Full Text] [Related]
29. Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis.
Ishaq H; Tariq W; Talha KM; Palraj BRV; Sohail MR; Baddour LM; Mahmood M
Infection; 2021 Oct; 49(5):803-811. PubMed ID: 33394368
[TBL] [Abstract][Full Text] [Related]
30. Impact of Vancomycin MIC on Clinical Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin at an Institution with Suppressed MIC Reporting.
Adani S; Bhowmick T; Weinstein MP; Narayanan N
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378704
[TBL] [Abstract][Full Text] [Related]
31. Difference in agr dysfunction and reduced vancomycin susceptibility between MRSA bacteremia involving SCCmec types IV/IVa and I-III.
Jang HC; Kang SJ; Choi SM; Park KH; Shin JH; Choy HE; Jung SI; Kim HB
PLoS One; 2012; 7(11):e49136. PubMed ID: 23152862
[TBL] [Abstract][Full Text] [Related]
32. Methicillin-resistant Staphylococcus aureus bacteraemia and mortality in a teaching hospital.
Beeston CJ; Gupta R; Chadwick PR; Young RJ
Eur J Clin Microbiol Infect Dis; 2009 Jun; 28(6):585-90. PubMed ID: 19067002
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Vancomycin plus a β-Lactam versus Vancomycin Only for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
Truong J; Veillette JJ; Forland SC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133561
[TBL] [Abstract][Full Text] [Related]
34. Comparative epidemiology of bacteremia due to methicillin-resistant Staphylococcus aureus between older and younger adults: a propensity score analysis.
Kullar R; Rybak MJ; Kaye KS
Infect Control Hosp Epidemiol; 2013 Apr; 34(4):400-6. PubMed ID: 23466914
[TBL] [Abstract][Full Text] [Related]
35. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
Hos NJ; Jazmati N; Stefanik D; Hellmich M; AlSael H; Kern WV; Rieg S; Wisplinghoff H; Seifert H; Kaasch AJ
J Infect; 2017 Mar; 74(3):248-259. PubMed ID: 28017826
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia.
Takesue Y; Nakajima K; Takahashi Y; Ichiki K; Ishihara M; Wada Y; Tsuchida T; Uchino M; Ikeuchi H
J Infect Chemother; 2011 Feb; 17(1):52-7. PubMed ID: 20625789
[TBL] [Abstract][Full Text] [Related]
37. Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis.
Li Z; Zhuang H; Wang G; Wang H; Dong Y
BMC Infect Dis; 2021 Jan; 21(1):74. PubMed ID: 33446122
[TBL] [Abstract][Full Text] [Related]
38. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
[TBL] [Abstract][Full Text] [Related]
39. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
40. Timing of initiating glycopeptide therapy for methicillin-Resistant Staphylococcus aureus bacteremia: the impact on clinical outcome.
Lee CH; Chien CC; Liu JW
ScientificWorldJournal; 2013; 2013():457435. PubMed ID: 23401670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
